一组甲基化微小RNA生物标志物用于识别溃疡性结肠炎相关结直肠癌高危患者
研究纳入日本2个独立队列2005至2015年间238例溃疡性结肠炎患者的387份结直肠组织标本,采用亚硫酸氢盐焦磷酸测序检测MIR1、MIR9、MIR124、MIR137、MIR34B/C甲基化。直肠黏膜miRNA甲基化面板区分伴或不伴异型增生或癌的UC患者,评估队列曲线下面积0.81,验证队列0.78。
要点
- 无肿瘤UC患者直肠组织MIR1、MIR9、MIR124、MIR137甲基化水平显著高于近端黏膜,且与年龄和UC病程相关。
- 异型增生或癌患者样本中所有miRNA甲基化显著高于无肿瘤患者。
- 直肠黏膜MIR137甲基化为UC相关结直肠癌的独立危险因素。
核心结论
- 在评估和验证队列中,伴异型增生或癌的UC患者直肠黏膜样本存在特定miRNA甲基化,该模式也与患者年龄相关,可能用于识别UC-CRC风险最高的患者。
- 研究结果为UC-CRC患者直肠黏膜存在场缺陷提供了证据。
研究设计与样本
- 研究从日本2个独立队列于2005至2015年间收集238例UC患者(152例无肿瘤、17例异型增生、69例UC相关结直肠癌)的387份结直肠组织标本,用亚硫酸氢盐焦磷酸测序定量miRNA甲基化。
- 验证研究纳入90例无UC患者和61例UC相关异型增生或癌患者样本,以确认UC患者非肿瘤直肠黏膜特定miRNA甲基化模式与UC-CRC风险的关联。
主要发现
- 无肿瘤UC患者直肠组织MIR1、MIR9、MIR124、MIR137甲基化水平显著高于近端黏膜,直肠黏膜甲基化水平与年龄和UC病程相关。
- 异型增生或癌患者样本中所有miRNA甲基化显著高于无肿瘤患者样本。
- 受试者工作特征分析显示直肠黏膜miRNA甲基化水平能准确区分伴与不伴癌的患者。
- 直肠黏膜MIR137甲基化是UC-CRC的独立危险因素。
- 一组miRNA甲基化面板在评估队列区分UC患者伴或不伴异型增生或癌的曲线下面积为0.81,验证队列为0.78。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Methylation of specific microRNAs (miRNAs) often occurs in an age-dependent manner, as a field defect in some instances, and may be an early event in colitis-associated carcinogenesis. We aimed to determine whether specific mRNA signature patterns (MIR1, MIR9, MIR124, MIR137, MIR34B/C) could be used to identify patients with ulcerative colitis (UC) who are at increased risk for colorectal neoplasia. METHODS: We obtained 387 colorectal tissue specimens collected from 238 patients with UC (152 without neoplasia, 17 with dysplasia, and 69 with UC-associated colorectal cancer [UC-CRC]), from 2 independent cohorts in Japan between 2005 and 2015. We quantified methylation of miRNAs by bisulfite pyrosequencing analysis. We analyzed clinical data to determine whether miRNA methylation patterns were associated with age, location, or segment of the colorectum (cecum, transverse colon, and rectum). Differences in tissue miRNA methylation and expression levels were compared among samples and associated with cancer risk using the Wilcoxon, Mann-Whitney, and Kruskal-Wallis tests as appropriate. We performed a validation study of samples from 90 patients without UC and 61 patients with UC-associated dysplasia or cancer to confirm the association between specific methylation patterns of miRNAs in non-tumor rectal mucosa from patients with UC at risk of UC-CRC. RESULTS: Among patients with UC without neoplasia, rectal tissues had significantly higher levels of methylation levels of MIR1, MIR9, MIR124, and MIR137 than in proximal mucosa; levels of methylation were associated with age and duration of UC in rectal mucosa. Methylation of all miRNAs was significantly higher in samples from patients with dysplasia or CRC compared with samples from patients without neoplasia. Receiver operating characteristic analysis revealed that methylation levels of miRNAs in rectal mucosa accurately differentiated patients with CRC from those without. Methylation of MIR137 in rectal mucosa was an independent risk factor for UC-CRC. Methylation patterns of a set of miRNAs (panel) could discriminate discriminate UC patients with or without dysplasia or CRC in the evaluation cohort (area under the curve, 0.81) and the validation cohort (area under the curve, 0.78). CONCLUSIONS: In evaluation and validation cohorts, we found specific miRNAs to be methylated in rectal mucosal samples from patients with UC with dysplasia or CRC compared with patients without neoplasms. This pattern also associated with patient age and might be used to identify patients with UC at greatest risk for developing UC-CRC. Our findings provide evidence for a field defect in rectal mucosa from patients with UC-CRC.
引用
- Toiyama Y, Okugawa Y, Tanaka K, et al. A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated Colorectal Cancer. Gastroenterology. 2017. PMID: 28847750. doi:10.1053/j.gastro.2017.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。